Full history for every metric is available with a Kvantra account
Ulisse Biomed S.p.A. (UBM.MI)
Key financial summary
Financials in EUR| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Operating profit | €m | -1 | -2 | |||||
| Net profit | €m | -1 | 0 | -1 | -1 | -5 | -1 | -1 |
| EPS reported | € | -0.06 | -0.03 | |||||
| Operating cashflow per share | € | -0.06 | -0.06 | |||||
| Capex per share | € | 0.00 | 0.00 | |||||
| FCF per share | € | -0.06 | -0.06 | |||||
| Free cash flow | €m | -2 | -1 | |||||
| Net debt | €m | -1 | -0 | |||||
| Book value equity | €m | 30 | 21 | |||||
| Book value per share | € | 1.28 | 0.87 | |||||
| Number of shares | m | 23.82 | 24.48 | |||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.59 | 0.92 | |||||
| P/S LTM | x | 44.16 | 34.71 | |||||
| P/FCF LTM | x | -11.67 | -30.46 | |||||
| EV/EBITDA LTM | x | -15.70 | 8.42 | |||||
| EV/Sales LTM | x | 40.74 | 34.61 | |||||
| Earnings Yield LTM | % | -8.12% | -7.62% | |||||
| FCF Yield | % | -8.57% | -3.28% | |||||
| Quality | ||||||||
| ROE | % | -4.80% | -5.06% | |||||
| ROIC | % | -4.74% | -4.74% | |||||
| Operating margin | % | -355.54% | -355.54% | |||||
| Gross margin | % | 51.14% | 51.14% | |||||
| FCF/Sales | % | -378.38% | -378.38% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +515.92% | +34.40% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1,169.82 | -0.64 | |||||
| Net Debt/EBITDA | x | 1.32 | 1.32 | |||||
| EBIT/Net interest | x | -1,736.35 | -1,736.35 | |||||
| Net debt/market cap | % | -7.75% | -0.29% | |||||
| Net debt/Equity | x | -0.05 | -0.00 | |||||
| Gross debt/equity | x | 0.00 | 0.05 | |||||
Company overview
Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in healthcare diagnostics. The company develops and markets a diverse range of innovative platforms and products designed for disease detection. Central to its offerings is the Sagitta platform, which encompasses specialized tests such as Ladymed/HPV Selfy for human papillomavirus screening, CoronaMelt for identifying SARS-CoV-2, and CoronaMelt Var for detecting and genotyping SARS-CoV-2 variants. Sagitta also provides UlisseFaster, a vital reagent used for the pre-treatment of biological samples, alongside various diagnostic tools for sexually transmitted infections and for detecting HPV associated with oropharyngeal cancers. Beyond Sagitta, Ulisse Biomed boasts the NanoHybrid platform, an advanced multi-modal biomolecule system that utilizes DNA/PNA technology to directly identify specific antibodies and protein analytes from serum or whole blood samples. Its portfolio is further enhanced by the Aptavir platform, dedicated to the development and manufacturing of synthetic nucleic acid molecules aimed at curtailing the infectiousness of pathogens. Established in 2015, Ulisse Biomed S.p.A. operates from its headquarters in Udine, Italy.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ulisse Biomed S.p.A. (UBM.MI)
Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in healthcare diagnostics. The company develops and markets a diverse range of innovative platforms and products designed for disease detection. Central to its offerings is the Sagitta platform, which encompasses specialized tests such as Ladymed/HPV Selfy for human papillomavirus screening, CoronaMelt for identifying SARS-CoV-2, and CoronaMelt Var for detecting and genotyping SARS-CoV-2 variants. Sagitta also provides UlisseFaster, a vital reagent used for the pre-treatment of biological samples, alongside various diagnostic tools for sexually transmitted infections and for detecting HPV associated with oropharyngeal cancers. Beyond Sagitta, Ulisse Biomed boasts the NanoHybrid platform, an advanced multi-modal biomolecule system that utilizes DNA/PNA technology to directly identify specific antibodies and protein analytes from serum or whole blood samples. Its portfolio is further enhanced by the Aptavir platform, dedicated to the development and manufacturing of synthetic nucleic acid molecules aimed at curtailing the infectiousness of pathogens. Established in 2015, Ulisse Biomed S.p.A. operates from its headquarters in Udine, Italy.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free